Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of once-daily oral KSP-0243 in mild-to-moderate ulcerative colitis
2022-000942-14Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing KSP-0243 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2024; status: completed.
02
Drugs
KSP-0243
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-000942-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000942-14.